Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Completed · Phase 3

Conditions studied: Psoriasis

In brief

The two objectives of this study were to evaluate long-term efficacy and safety of adalimumab treatment in participants who had moderate to severe chronic plaque psoriasis and to evaluate the effectiveness of adalimumab retreatment in participants who had therapeutic response to adalimumab and were then withdrawn from adalimumab treatment.

Key facts

Study ID

NCT00195676

Run by

Abbott

People needed

1469

Starts

2004-05-01

Expected to finish

2009-10-01

Last updated by the study team

2011-04-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject was age 18 or older and in good health (Investigator discretion) with a recent stable medical history.
• Subjects who met the requirements from previous adalimumab psoriasis study participation.

You may not qualify if…

• Subject considered by the Investigator, for any reason, to be an unsuitable candidate for the study.
• Female subject who was pregnant or breast-feeding or considering becoming pregnant.

Where it is running

• Site Reference ID/Investigator# 1259 — Buckner 13075 PI, Alabama, United States
• Site Reference ID/Investigator# 2427 — Scottsdale, Arizona, United States
• Site Reference ID/Investigator# 2433 — Tucson, Arizona, United States
• Site Reference ID/Investigator# 100 — Little Rock, Arkansas, United States
• Site Reference ID/Investigator# 1798 — Bakersfield, California, United States
• Site Reference ID/Investigator# 122 — Fresno, California, United States
• Site Reference ID/Investigator# 1669 — Irvine, California, United States
• Site Reference ID/Investigator# 1285 — Oceanside, California, United States
• Site Reference ID/Investigator# 86 — San Diego, California, United States
• Site Reference ID/Investigator# 1679 — Santa Monica, California, United States
• Site Reference ID/Investigator# 1677 — Torrance, California, United States
• Site Reference ID/Investigator# 1269 — Longmont, Colorado, United States
• Site Reference ID/Investigator# 1275 — New Haven, Connecticut, United States
• Site Reference ID/Investigator# 96 — Jacksonville, Florida, United States
• Site Reference ID/Investigator# 2431 — Pinellas Park, Florida, United States
• Site Reference ID/Investigator# 1273 — South Miami, Florida, United States
• Site Reference ID/Investigator# 2432 — West Palm Beach, Florida, United States
• Site Reference ID/Investigator# 98 — Alpharetta, Georgia, United States
• Site Reference ID/Investigator# 1674 — Newnan, Georgia, United States
• Site Reference ID/Investigator# 1670 — Snellville, Georgia, United States
• Site Reference ID/Investigator# 1264 — Chicago, Illinois, United States
• Site Reference ID/Investigator# 1801 — Maywood, Illinois, United States
• Site Reference ID/Investigator# 1681 — Springfield, Illinois, United States
• Site Reference ID/Investigator# 1267 — Indianapolis, Indiana, United States
• Site Reference ID/Investigator# 1263 — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.